Disproportionate Preponderance of HPV Genotypes Associated with Anogenital Warts Among HIV-positive MSM

Overview

Journal Front Public Health

Specialty Public Health

Date 2024 Oct 7

PMID 39371203

Authors

Wegene Borena

Maria Kitchen

Martin Gisinger

Ninon Taylor

Hannes Oberkofler

Diyani Dewasurendra

Andreas Widschwendter

Heribert Stoiber

Dorothee von Laer

Mario Sarcletti

Affiliations

Soon will be listed here.

Abstract

Background: In this study, we characterized the HPV genotype distribution in a population of 489 adults already positive for HPV DNA. The study population was divided into two groups: 244 HIV-positive (HIV+) men who have sex with men (MSM) undergoing routine anal screening for sexually transmitted diseases (STDs) and 245 women undergoing routine cervical cancer screening. Acknowledging the fact that women and MSM represent two independent circles of sexual practices, which are-largely-exclusive of each other, we were interested in determining if particular genotypes of human papillomavirus (HPV) disproportionately predominate in one of these circles compared to the other.

Results: HIV+ MSM are significantly more likely to be infected with multiple genotypes at a time, with an odds ratio (OR) of 9.30 (95% confidence interval [CI]: 3.91-22.1) and a -value of <0.001. In addition, multivariable-adjusted logistic regression analysis showed that anal swab samples were significantly more likely to harbor lrHPV infections, with an OR of 6.67 (95% CI: 2.42-18.4) and a -value of <0.001, in particular, HPV 6, with an OR of 8.92 (95% CI: 3.84-20.7) compared to cervical samples of screening women.

Conclusion: Given the significant impact of recurrent anogenital warts (AGWs) on quality of life and the accompanying predisposition to invasive anal cancer, our data underscore the critical need for HPV vaccination. This includes expanding vaccination eligibility to include both boys and adults within high-risk populations.

Citing Articles

A review of the carcinogenic potential of human papillomavirus (HPV) in urological cancers.

Zolfi E, Khaleghi Mehr F, Emtiazi N, Moradi Y Virol J. 2025; 22(1):53.

PMID: 40022189 PMC: 11871667. DOI: 10.1186/s12985-025-02682-1.

Human Papillomavirus-Related Cancer Vaccine Strategies.

Cai X, Xu L Vaccines (Basel). 2024; 12(11).

PMID: 39591193 PMC: 11598756. DOI: 10.3390/vaccines12111291.

References

Arnold J, Byrne M, Monroe A, Abbott S . The Risk of Anal Carcinoma After Anogenital Warts in Adults Living With HIV. JAMA Dermatol. 2021; 157(3):283-289. PMC: 7807394. DOI: 10.1001/jamadermatol.2020.5252. View

Guimera N, Lloveras B, Alemany L, Iljazovic E, Shin H, Jung-Il S . Laser capture microdissection shows HPV11 as both a causal and a coincidental infection in cervical cancer specimens with multiple HPV types. Histopathology. 2013; 63(2):287-92. DOI: 10.1111/his.12137. View

Gao W, Weng J, Gao Y, Chen X . Comparison of the vaginal microbiota diversity of women with and without human papillomavirus infection: a cross-sectional study. BMC Infect Dis. 2013; 13:271. PMC: 3684509. DOI: 10.1186/1471-2334-13-271. View

Paavonen J, Jenkins D, Bosch F, Naud P, Salmeron J, Wheeler C . Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007; 369(9580):2161-2170. DOI: 10.1016/S0140-6736(07)60946-5. View

Yang E, Quick M, Hanamornroongruang S, Lai K, Doyle L, McKeon F . Microanatomy of the cervical and anorectal squamocolumnar junctions: a proposed model for anatomical differences in HPV-related cancer risk. Mod Pathol. 2015; 28(7):994-1000. PMC: 4490106. DOI: 10.1038/modpathol.2015.54. View

Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch F, de Sanjose S . Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010; 202(12):1789-99. DOI: 10.1086/657321. View

de Pokomandy A, Rouleau D, Ghattas G, Vezina S, Cote P, Macleod J . Prevalence, clearance, and incidence of anal human papillomavirus infection in HIV-infected men: the HIPVIRG cohort study. J Infect Dis. 2009; 199(7):965-73. DOI: 10.1086/597207. View

Scheurer M, Tortolero-Luna G, Adler-Storthz K . Human papillomavirus infection: biology, epidemiology, and prevention. Int J Gynecol Cancer. 2005; 15(5):727-46. DOI: 10.1111/j.1525-1438.2005.00246.x. View

Shvetsov Y, Hernandez B, McDuffie K, Wilkens L, Zhu X, Ning L . Duration and clearance of anal human papillomavirus (HPV) infection among women: the Hawaii HPV cohort study. Clin Infect Dis. 2009; 48(5):536-46. PMC: 2756215. DOI: 10.1086/596758. View

10.

Blomberg M, Friis S, Munk C, Bautz A, Kjaer S . Genital warts and risk of cancer: a Danish study of nearly 50 000 patients with genital warts. J Infect Dis. 2012; 205(10):1544-53. DOI: 10.1093/infdis/jis228. View

11.

Bosch F, Lorincz A, Munoz N, Meijer C, Shah K . The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002; 55(4):244-65. PMC: 1769629. DOI: 10.1136/jcp.55.4.244. View

12.

Nordenvall C, Chang E, Adami H, Ye W . Cancer risk among patients with condylomata acuminata. Int J Cancer. 2006; 119(4):888-93. DOI: 10.1002/ijc.21892. View

13.

Joura E, Giuliano A, Iversen O, Bouchard C, Mao C, Mehlsen J . A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015; 372(8):711-23. DOI: 10.1056/NEJMoa1405044. View

14.

Smith B, Zolnik C, Usyk M, Chen Z, Kaiser K, Nucci-Sack A . Distinct Ecological Niche of Anal, Oral, and Cervical Mucosal Microbiomes in Adolescent Women. Yale J Biol Med. 2016; 89(3):277-284. PMC: 5045137. View

15.

Egawa N, Doorbar J . The low-risk papillomaviruses. Virus Res. 2017; 231:119-127. DOI: 10.1016/j.virusres.2016.12.017. View

16.

Giuliano A, Nyitray A, Kreimer A, Pierce Campbell C, Goodman M, Sudenga S . EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection. Int J Cancer. 2014; 136(12):2752-60. PMC: 4297584. DOI: 10.1002/ijc.29082. View

17.

zur Hausen H . Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst. 2000; 92(9):690-8. DOI: 10.1093/jnci/92.9.690. View

18.

Borena W, Luckner-Hornischer A, Katzgraber F, Laer D . Factors affecting HPV vaccine acceptance in west Austria: Do we need to revise the current immunization scheme?. Papillomavirus Res. 2017; 2:173-177. PMC: 5886907. DOI: 10.1016/j.pvr.2016.10.001. View

19.

Adebamowo S, Olawande O, Famooto A, Dareng E, Offiong R, Adebamowo C . Persistent Low-Risk and High-Risk Human Papillomavirus Infections of the Uterine Cervix in HIV-Negative and HIV-Positive Women. Front Public Health. 2017; 5:178. PMC: 5519520. DOI: 10.3389/fpubh.2017.00178. View

20.

Ndizeye Z, Broeck D, Lebelo R, Bogers J, Benoy I, Van Geertruyden J . Prevalence and genotype-specific distribution of human papillomavirus in Burundi according to HIV status and urban or rural residence and its implications for control. PLoS One. 2019; 14(6):e0209303. PMC: 6592514. DOI: 10.1371/journal.pone.0209303. View